Sangamo治疗机构报告季度损失,但收入激增,股价上涨。 Sangamo Therapeutics reports a quarterly loss but sees revenue surge and stock price rise.

Sangamo治疗公司报告,季度每股损失0.11美元,估计损失2美元,收入增加270.1%至755万美元。 Sangamo Therapeutics reported a quarterly loss of $0.11 per share, missing estimates by $0.02, with revenue up 270.1% to $7.55 million. 开发基因组药物的生物制药公司在公布收入时的股票价格上升至1.01美元,尽管其净负差为257.87%。 The biopharmaceutical company, which develops genomic medicines, saw its stock price increase to $1.01 on the earnings announcement, though it had a negative net margin of 257.87%. 该公司的年损失为9 790万美元,获一致评为“Moderate Buy”,目标价格为580美元。 The company's annual loss was $97.9 million, with a consensus rating of "Moderate Buy" and a target price of $5.80.